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It is estimated that four million people in the United Kingdom have either osteo-
arthritis or rheumatoid arthritis. With the extension in lifespan seen in recent
decades, the number is thought to be increasing. Many of the above will be
treated with non-steroidal anti-inflammatory drugs.
Lithium has been proven to be useful in the prophylaxis ofaffective disorders. It is
also used in refractory depression and mania and has been advocated in those
with aggressive outbursts. McCreadie et all found it being taken by 0-77/1,000
people in south west Scotland. Extrapolated to the United Kingdom this would
mean lithium is taken by approximately 40,000 patients.
With the increasing use of non-steroidal anti-inflammatory drugs and lithium,
the possibility of interactions are more likely. Seven reports of patients taking
both agents detail interactions leading to a toxic elevation of the serum lithium
level. The non -steroidal anti-inflammatory drugs previously implicated have
been piroxicam,2 3 4 mefanamic acid,5 6 indomethacin7 and phenylbutazone.8
We have recently observed two patients with affective disorders who were main-
tained on lithium carbonate but then developed lithium toxicity following
inadvertent prescription of non -steroidal anti-inflammatory drugsbytheirgeneral
practitioner.
REPORTS
CASE 1. A 73-year-old widow had been suffering from annual episodes of
endogenous depression for five years. She had previously responded to tricyclic
anti-depressants and electroconvulsive therapy. Her physical health had been
excellent except for menorrhagia which required hysterectomy at age 52, and
osteo -arthritis. She had no renal or hepatic impairment and was on no medic-
ation except that for her psychiatric condition. Maintenance treatment with anti-
depressant drugs proved unsatisfactory because of tremor and tinnitus. Lithium
carbonate (Priadel, Delandale) 400 mg at night was commenced in July, 1987.
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At this dose she achieved serum lithium concentrations in the range 0 5-0 6
mmol/1 and remained clinically euthymic. In March, 1988 her serum lithium was
found to be 1 * 15 mmol/1, an increase from 0*5 mmol/1 one month previously,
and she suffered increasing coarse tremor. No other symptoms of toxicity were
noted. Analysis of full blood count, liver function tests and serum urea, electro-
lytes and creatinine were essentially unchanged, and were within the normal
laboratory range. There was no clinical or laboratory evidence of urinary tract
infection. She denied altering her medication at any time. Lithium dosage was
reduced to 200 mg at night and serum lithium concentration fell to 0 3 mmol/1
in May, 1988. It was not until this visit to the clinic that she mentioned she had
been commenced on piroxicam (Feldene, Pfizer) 20 mg daily in February, 1988,
byher general practitioner, forarthritisin hershoulder. Herdiscomfort had settled
and she had stopped the piroxicam prior to the May visit. The lithium was
increased to 400 mg at night again and her serum lithium concentration now
remains stable at 0*5 -0*7 mmol/1.
CASE 2. A 53-year-old lady with a history of severe bipolar affective disorder
over 35 years was attending as a day patient after a nine month admission
with mania. She had suffered from infective hepatitis while in Africa 15 years
previously, and had been overweight for some years which contributed to her
osteo-arthritis. She had become hypothyroid as a result of lithium therapy. Her
clinical state was stable on lithium carbonate (Priadel, Delandale) 400 mg twice
daily, pimozide (Orap, Janssen) 12 mg four times daily, ibuprofen 400 mg three
times dailyand thyroxine 50 mcg daily. She used no other medications. Episodic-
ally she would complain of unsteadiness and tremor. On these occasions her
serum lithium concentration, which was usually in the range 0 7-0 09 mmol/1,
would be above 1 *2 mmol/1. Initially it wasfelt this might be related to erratic use
of her medication. Serum urea, electrolytes, creatinine and liver function tests
had been stable over several years and remained within normal laboratory values
despite fluctuating serum lithium levels. There was no clinical or laboratory
evidence of salt or water depletion. Though the dose of neuroleptic was high,
this had been found necessary to control her illness and her tremor was not
parkinsonian. It was decided to give out her tablets on a daily ratherthan a weekly
basis, but despite this her serum lithium concentration rose from 0 9 mmol/1
(on 7.9.87) to 1 5 mmol/l (on 23.10.87). We then suspected that varying use
of ibuprofen was causing these fluctuations. Her serum lithium was stabilised at
0 7 mmol /I on 400 mg lithium carbonate per day. Withdrawal of ibuprofen was
then followed by a fall in serum lithium to 0-4 mmol/1 after one week, and
re-introduction was followed by a rise of serum lithium to 0 7 mmol/I.
DISCUSSION
Lithium carbonate is an effective compound in the prophylaxis of unipolar and
bipolar affective disorders but it has a narrow therapeutic index and drug inter-
actions can cause fatalities. It is now clear but perhaps not widely recognised that
some non-steroidal anti-inflammatory drugs can elevate serum lithium concen-
trations into the toxic range and this report adds ibuprofen to the list. Even
patients maintained at the lower end of the therapeutic range for serum lithium
may present with toxic symptoms or fluctuating lithium concentrations. Given the
increasing use of lithium carbonate for recurrent affective disorder in older
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patients, who are more likely to be prescribed non-steroidal anti-inflammatory
drugs, this interaction requires greater attention. Furthermore it is particularly
general practitioners who need to be aware of this as it is they, rather than the
psychiatrist, who are most likely to prescribe one of these analgesic agents for a
transient or newly emergent inflammatory problem. Our first case in particular
highlights this problem, and the patient developed signs oftoxicity that continued
for some time before the next appointment at the hospital. We would advise all
doctors to consult the relevant section on drug interactions in the British National
Formulary before prescribing any adjunctive medication to a patient on lithium.
Certain drugs, such as piroxicam, may be more potent than others. The mode of
interaction is unclear but may be related to renal prostaglandin function.6'8 Non-
steroidal anti-inflammatory agents act to reduce prostaglandin synthesis, by
inhibiting thecyclo
-oxygenase enzyme system. Sodium excretionissubsequently
reduced in the kidney and this lowers lithium clearance.9 Other non-steroidal
anti-inflammatory drugs implicated also have powerful prostaglandin inhibitory
action.'0 Theimplicationofibuprofen, which isnowavailable without prescription,
leads to further concern.
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